1) Manganxiao
慢肝消
1.
Studies on the Characteristics of Traditional Chinese Medical Syndrome of Alcoholic Liver Fibrorosis and on the Molecular Mechanisms of Manganxiao Compound Anti-Fibrorosis;
酒精性肝纤维化中医证候特点和慢肝消抗酒精性肝纤维化的分子机制
2) Chronic hepatitis
慢性肝炎
1.
The analyse and the result that Chronic hepatitis B patient take place the variation of YMDD detectioned with FQ-PCR;
191例慢性肝炎患者服用拉米夫定后乙型肝炎病毒YMDD变异的检测及分析
2.
Analyses of factors influencing serum fibrotic markers in patients with chronic hepatitis;
慢性肝炎患者血清纤维化指标影响因素的探讨
3.
Investigation of clinical value of of platelet count in patients with chronic hepatitis and liver cirrhosis;
慢性肝炎及肝硬化患者血小板计数的临床探讨
3) chronic liver disease
慢性肝病
1.
Changes of serum argininosuccinate lyase levels in patients with chronic liver diseases;
慢性肝病患者血清精氨[基]琥珀酸裂合酶的变化
2.
A survey of influencing factors of chronic liver disease patients with sleep disorder;
慢性肝病病人睡眠障碍的影响因素调查
3.
A study on sleeping state of patients with chronic liver disease;
慢性肝病病人的睡眠状况研究
4) Chronic Hepatitis B
慢性乙肝
1.
Retrospective Study on Relationship between TCM Type of Syndromes and Replication of Virus in Patients with Chronic Hepatitis B;
慢性乙肝中医证型与病毒复制关系的回顾性研究
2.
Effect of IFN-α2b on expression of CD25 and its mRNA in patients with chronic hepatitis B;
干扰素对慢性乙肝患者CD25及mRNA表达影响
3.
Effect of Ruanganchengji treatment on plasma levels of TGF-β1, TIMP-1and MMP-1 in patients with chronic hepatitis B;
软肝冲剂对慢性乙肝患者血浆中的TGF-β1,MMP-1和TIMP-1浓度的影响
5) Chronic liver diseases
慢性肝病
1.
Objective To study the correlation between serum level of PCⅢ and the degree of liver fibrosis in patients with chronic liver diseases.
目的:探讨慢性肝病患者血清Ⅲ型前胶原(PCⅢ)水平与肝纤维化病变程度的相关性及进程的分级判定作用。
2.
The content of serum HA and SCG is determined by RIA in 150 patients of chronic liver diseases.
结果表明 :慢性肝病患者血清中 HA和 SCG的含量显著高于对照组 ( P<0 。
3.
Objective:To reevaluate the blood endotoxin concentration in patients with chronic liver diseases by means of dynamic turbidimetric analysis.
目的:采用动态浊度法对慢性肝病患者血、腹水中内毒素水平进行再评估。
6) Chronic hepatopathy
慢性肝病
1.
Application of protein chip technology for investigation of changes of various serum cytokines in patients with chronic hepatopathy;
应用蛋白芯片技术观察慢性肝病患者血清细胞因子的变化规律
2.
Methods 18 normal rats and 36 chronic hepatopathy rats divided into:①normal ofloxacin protective group; ②normal PGE2 immuno-intervention group;③hepatopathy ofloxacin protective group;④hepatopathy PGE2 immuno-intervention combined ofloxacin protective group;⑤hepatopathy negative group; ⑥ hepa.
方法取18只正常大鼠和36只慢性肝病大鼠,随机分成:①正常氧氟沙星治疗组;②正常PGE2免疫干预与氧氟沙星联合保护组;③肝病氧氟沙星等药物治疗组;④肝病PGE2免疫干预与氧氟沙星等药物联合保护组;⑤肝病大鼠阴性对照组;⑥肝病大鼠Vv攻击对照组(n=9)。
3.
Methods: Eighteen chronic hepatopathy rats which were prepared by carbon tetrachloride were divided into Vv attack group and control group to make multiple organ dysfunction hepatopathy rat models of Vv lethal infection (5.
方法：采用四氯化碳制备慢性肝病大鼠18只,分Vv攻击和肝病大鼠对照组(n=9),Vv致死性感染多器官损伤肝病大鼠模型(5。
补充资料：马洛替脂，慢肝灵
药物名称：马洛替脂
英文名：Malotilate
别名： 马洛替脂，慢肝灵
适应症：
用于防治慢性肝炎、肝硬变代偿期和晚期血吸虫病等慢性肝病伴低白蛋白血症。
用量用法：
口服：每次０．２ｇ，每日３次。用药期间如转氨酶或胆红素明显升高者应停药观察。
注意事项：
少数患者可出现头痛、困倦、恶心、腹胀、口渴、皮疹、瘙痒、口炎等；偶有红细胞及白细胞减少、嗜酸粒细胞增加。对本品过敏患者及血清转氨酶或胆红素明显增高的失代偿肝病患者忌用。孕妇、乳儿及小儿慎用或不用。
规格： 片剂：０．１ｇ、０．２ｇ。
类别：肝胆疾病辅助用药
英文名：Malotilate
别名： 马洛替脂，慢肝灵
适应症：
用于防治慢性肝炎、肝硬变代偿期和晚期血吸虫病等慢性肝病伴低白蛋白血症。
用量用法：
口服：每次０．２ｇ，每日３次。用药期间如转氨酶或胆红素明显升高者应停药观察。
注意事项：
少数患者可出现头痛、困倦、恶心、腹胀、口渴、皮疹、瘙痒、口炎等；偶有红细胞及白细胞减少、嗜酸粒细胞增加。对本品过敏患者及血清转氨酶或胆红素明显增高的失代偿肝病患者忌用。孕妇、乳儿及小儿慎用或不用。
规格： 片剂：０．１ｇ、０．２ｇ。
类别：肝胆疾病辅助用药
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条